Posts by: Iqra Mumal

Expression of the protein ANK1 (ankyrin repeat domain-containing protein) is four fold higher in the microglia of patients with Alzheimer’s disease (AD). Microglia are a type of immune cell found ... Read more

June 8, 2017

Lundbeck Obtains Rights to Research that Targets Immune Checkpoint Pathways in Alzheimer’s

News

Lundbeck, a global pharmaceutical company specializing in therapies for neurological disorders, has obtained the rights to IBC’s (ImmunoBrain Checkpoint) groundbreaking research into treatment for Alzheimer’s disease. “IBC has a unique ... Read more

June 5, 2017June 5, 2017

Phase 1 Trial Begins Evaluating Safety of Focused Ultrasound in Alzheimer’s Patients

News

Insightec’s new platform, Exablate Neuro, is to be a part of the first-ever clinical trial (NCT02986932) evaluating the safety and feasibility of opening the blood-brain barrier (BBB) in Alzheimer’s ... Read more